Product Description
BCL10 Antibody | 13-075 | ProSci
Host: Rabbit
Reactivity: Human, Mouse
Homology: N/A
Immunogen: A synthetic peptide of human BCL10
Research Area: Apoptosis, Cancer, Cell Cycle, Immunology, Signal Transduction
Tested Application: WB, IHC, IF, Flow
Application: WB: 1:500 - 1:1000
IHC: 1:50 - 1:100
IF: 1:20 - 1:50
Flow: 1:20 - 1:50
Specificiy: N/A
Positive Control 1: Mouse ovary
Positive Control 2: N/A
Positive Control 3: N/A
Positive Control 4: N/A
Positive Control 5: N/A
Positive Control 6: N/A
Molecular Weight: Observed: 32kDa
Validation: N/A
Isoform: N/A
Purification: Affinity purification
Clonality: Polyclonal
Clone: N/A
Isotype: IgG
Conjugate: Unconjugated
Physical State: Liquid
Buffer: PBS with 0.02% sodium azide, pH7.3.
Concentration: N/A
Storage Condition: Store at 4˚C (regular) or -20˚C (long term) . Avoid freeze / thaw cycles.
Alternate Name: Bcl-10 Antibody: CLAP, mE10, CIPER, c-E10, CARMEN, CLAP, CARD-containing molecule enhancing NF-kappa-B, Bcl-10
User Note: Optimal dilutions for each application to be determined by the researcher.
BACKGROUND: This gene was identified by its translocation in a case of mucosa-associated lymphoid tissue (MALT) lymphoma. The protein encoded by this gene contains a caspase recruitment domain (CARD) , and has been shown to induce apoptosis and to activate NF-kappaB. This protein is reported to interact with other CARD domain containing proteins including CARD9, 10, 11 and 14, which are thought to function as upstream regulators in NF-kappaB signaling. This protein is found to form a complex with MALT1, a protein encoded by another gene known to be translocated in MALT lymphoma. MALT1 and this protein are thought to synergize in the activation of NF-kappaB, and the deregulation of either of them may contribute to the same pathogenetic process that leads to the malignancy. Alternative splicing results in multiple transcript variants.